Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Franck Priou"'
Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma
Autor:
Laurence Albiges, Loic Mourey, Bernard Escudier, Guillettno De Velasco, Edouard Auclin, Yann-Alexandre Vano, Petri Bono, Philippe Barthélémy, Marie Auvray, Marine Gross-Goupil, Gwenaelle Gravis, Thomas Powles, Frederic Rolland, Guillaume Mouillet, Pirkko Kellokumpu-Lehtinen, Franck Priou
Publikováno v:
European Journal of Cancer. 108:33-40
Correction: Volume: 119 Pages: 200-201 DOI: 10.1016/j.ejca.2019.04.012 Published: SEP 2019 Background: Nivolumab-ipilimumab demonstrated a survival benefit over sunitinib in first-line setting for metastatic renal cell carcinomas (mRCCs) and is becom
Autor:
Jean-Christophe Eymard, Stéphanie Foulon, Remy Delva, Philippe Barthélémy, Eric Voog, Franck Priou, Carole Helissey, Raffaele Longo, Yann Neuzillet, Ali Hasbini, Pierre-Emmanuel Brachet, Karim Fizazi, Emeline Colomba, Sarah Flora Jonas, Carolina Saldana, Emmanuelle Bompas, Guilhem Roubaud, Delphine Borchiellini, Hakim Mahammedi, Nicolas Penel
Publikováno v:
Journal of Clinical Oncology. 39:5046-5046
5046 Background: Darolutamide (Daro) and enzamutamide (Enza) are both next generation androgen receptor inhibitors with demonstrated activity in men with CRPC. Although both agents are associated with survival improvement, their toxicity profiles are
Autor:
Nadine Houede, Remy Delva, David Zylberait, Laurent Miglianico, Philippe Beuzeboc, Philippe Gomez, Ivan Krakowski, Emmanuel Sevin, I. Latorzeff, Anne-Claire Hardy-Bessard, Frederic Rolland, Loic Mouret, Stéphane Oudard, Claude Linassier, Eugeniu Banu, Christine Abraham, Gwenaelle Gravis, Jean-Marc Ferrero, Alain Ravaud, Eric Voog, A. Caty, Jean-Léon Lagrange, Reza Elaidi, Gael Deplanque, Xavier Muracciole, Laurence Bozec, Stéphane Culine, Franck Priou
Publikováno v:
JAMA oncology. 5(5)
Importance Androgen-deprivation therapy (ADT) plus docetaxel is the standard of care in hormone-naive metastatic prostate cancer but is of uncertain benefit in a nonmetastatic, high-risk prostate cancer setting. Objective To assess the benefit of ADT
Autor:
Loic Mourey, Frederic Rolland, Guillermo Velasco, Thomas Powles, Yann-Alexandre Vano, Gwenaelle Gravis, Marine Gross-Goupil, Petri Bono, Marie Auvray, Laurence Albiges, Bernard Escudier, Edouard Auclin, Philippe Barthélémy, Guillaume Mouillet, Pirkko Kellokumpu-Lehtinen, Franck Priou
Publikováno v:
European Journal of Cancer. 119:200-201
Autor:
Christine Piprot-Choffat, Virginie Berger, Hélène Simon, Franck Priou, Philippe Bougnoux, Anne Mercier-Blas, Christelle Levy, Patrick Soulié, Jacques Bonneterre, Caroline Goupille
Publikováno v:
Cancer Research. 75:P3-13
Background: Long chain n-3 Polyunsaturated Fatty Acids (n-3 PUFA) of marine origin (docosahexaenoic acid, DHA and eicosapentaenoic acid, EPA) have been shown to increase sensitivity of cell lines to anthracyclins or taxanes. Preclinical studies and a
Autor:
Guilhem Bousquet, Loic Mourey, Michel Soulié, Stéphane Oudard, Franck Priou, Jérôme Dauba, Claude Linassier, Ali Hasbini, Igor Latorzeff, Claude El Kouri, Florence Joly, Marjorie Baciuchka, Gael Deplanque, Christine Theodore, Brigitte Laguerre, Jean Marc Ferrero, Frederic Rolland, Ivan Krakowski, Jean Luc Labourey, Remy Delva, Gwenaelle Gravis, Patricia Marino, Philippe Beuzeboc, Jean-Pascal Machiels, Damien Pouessel, Karim Fizazi, Muriel Habibian, Benjamin Esterni, Jean-François Berdah, Christian Platini, Sylvie Zanetta, Alain Ravaud, Jean-Christophe Eymard, Etienne Suc
Publikováno v:
European Journal of Cancer. 50:953-962
BACKGROUND: Toxicity, which is a key parameter in the evaluation of cancer treatments, can be underestimated by clinicians. We investigated differences between patients and physicians in reporting adverse events of androgen deprivation therapy (ADT)
Autor:
Gwenaelle Gravis, Federica Recine, Frederic Rolland, Tim Eisen, Laurence Albiges, Lisa Derosa, Cora N. Sternberg, Gwénaël Le Teuff, Anandagopal Srinivasan, Grant D. Stewart, Howard Gurney, Franck Priou, Andrea Biondo, Gregory Verhoest, Pierre Bigot, Kate Fife, Stéphane Culine, Christian Pfister, Jean-Michel Rodier, James Larkin, Bernard Escudier, J. Berger, A. Caty, C. Saldana, Philippe Barthélémy, Elodie Vauleon, Lisa Pickering, Helen Boyle, Jean-Christophe Bernhard, Christy Ralph, Emeline Colomba
Publikováno v:
European journal of cancer (Oxford, England : 1990). 80
Background Treatment of non–clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR)
Autor:
Geraldine Martineau, Stéphanie Foulon, Giulia Baciarello, Florence Joly, Remy Delva, Philippe Barthelemy, Yann Neuzillet, Franck Priou, Anne Sophie Hue, Karim Fizazi
Publikováno v:
Journal of Clinical Oncology. 37:TPS334-TPS334
TPS334 Background: In recent years, the treatment of mCRPC has evolved and next-generation androgen receptor (AR)-axis targeting drugs (enzalutamide (ENZ), and abiraterone) have been approved and are routinely used. Darolutamide (DARO) is a new next-
Autor:
Jean-Marie Boher, Igor Latorzeff, Stéphane Oudard, Florence Joly, Stéphane Culine, Muriel Habibian, Frederic Rolland, Ivan Krakowski, Gael Deplanque, Loic Mourey, Jean-Marc Ferrero, Remy Delva, Brigitte Laguerre, Gwenaelle Gravis, Christine Theodore, Karim Fizazi, Philippe Beuzeboc, Michel Soulié, Laurence Albiges, Franck Priou
Publikováno v:
European Urology
European Urology, 2016, 70, pp.256-262. ⟨10.1016/j.eururo.2015.11.005⟩
European Urology, Elsevier, 2016, 70, pp.256-262. ⟨10.1016/j.eururo.2015.11.005⟩
European Urology, 2016, 70, pp.256-262. ⟨10.1016/j.eururo.2015.11.005⟩
European Urology, Elsevier, 2016, 70, pp.256-262. ⟨10.1016/j.eururo.2015.11.005⟩
Background The role of chemotherapy in metastatic non castrate prostate cancer (mNCPC) is debated. Survival benefits of docetaxel (D) added to androgen-deprivation therapy (ADT) were shown in the CHAARTED trial in patients with metastatic high-volume
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a62a596522d50bf7c47cd0bd9856cbb6
https://www.hal.inserm.fr/inserm-03343628
https://www.hal.inserm.fr/inserm-03343628
Autor:
Stéphane Culine, A. Banu, Laure Fournier, Nina Arakelyan, Jacques Medioni, Bernard Escudier, Franck Priou, Brigitte Duclos, Stéphane Oudard, Eugeniu Banu, Annick Vieillefond, Frederic Rolland
Publikováno v:
Journal of Urology. 177:1698-1702
Collecting duct carcinoma of the kidney is a rare and aggressive neoplasm of the distal collecting tubules for which there is no established treatment. Since the histology of collecting duct carcinoma is similar to that of urothelial carcinoma, the s